Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RBP4 | P02753 | 10/20 | 0.43 |
| ▸ | GAA | P10253 | 2/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | HTR2C | P28335 | 4/20 | 0.40 |
| ▸ | HTR2B | P41595 | 2/20 | 0.40 |
| ▸ | HTR2A | P28223 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | DRD3 | P35462 | 1/20 | 0.37 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15743997 | 0.86 | HTR2C (0.41) | RBP4GAATDP1HTR2CHTR2B | |
| SCHEMBL13950176 | 0.83 | GAA (0.41) | RBP4GAATDP1HTR2CHTR2B | |
| SCHEMBL16181047 | 0.81 | HTR6 (0.42) | GAAGRM2MEN1KMT2A | |
| SCHEMBL16181048 | 0.80 | HSD11B1 (0.40) | HTR2CHTR2BHTR2A | |
| SCHEMBL16181071 | 0.78 | HTR6 (0.47) | GAATP53KMT2A | |
| SCHEMBL13970596 | 0.76 | HTR6 (0.46) | HTR2CMEN1KMT2A | |
| SCHEMBL13395501 | 0.75 | HTR2C (0.40) | RBP4GAATDP1HTR2CHTR2B | |
| SCHEMBL20794411 | 0.75 | RBP4 (0.40) | RBP4GAATDP1HTR2CHTR2B | |
| SCHEMBL28170632 | 0.75 | HTR2C (0.45) | RBP4GAATDP1HTR2CHTR2B | |
| SCHEMBL13547542 | 0.74 | HTR2C (0.40) | RBP4GAATDP1HTR2CHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8865707-B2 | Cholesteryl ester transfer protein inhibitors | MERCK SHARP & DOHME CORP. (US) | 2014-10-21 | — | — | US | disclosed |
| EP-1973546-B1 | CHOLESTERYL ESTER TRANSFER PROTEIN INHIBITORS | MERCK SHARP & DOHME (US) | 2012-06-13 | — | — | EP | disclosed |
| US-20090018054-A1 | Cholesteryl Ester Transfer Protein Inhibitors | MERCK SHARP & DOHME LLC | 2009-01-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090018054-A1 | Cholesteryl Ester Transfer Protein Inhibitors | CETP, APOB, MTTP | RBP4 333/4885GAA 1578/4885TDP1 1624/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.